Home > Insider Trading > Filing (0001104659-22-072798)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1622229	Cogent Biosciences Inc.	COGT	Pharmaceutical Preparations (2834)	465308248

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1802528	Fairmount Funds Management Llc	2001 Market Street, Suite 2500 Philadelphia PA 19103		No	No	Yes	Yes

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2022-06-16	1,200,000	$8.25	2,472,124	No	4	P	Indirect	Fairmount Healthcare Fund II LP

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Indirect	Fairmount Healthcare Fund II LP

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	286,851	Indirect	Fairmount Healthcare Fund LP

Reported Derivative Holdings

Sec. Name	Sec. Type	Price	Date	Expiration Date	Amount	Remaning Holdings	Nature of Ownership
Common Stock	Series A Convertible Preferred Stock	$0.00			2,978,500	11,914	Indirect
Common Stock	Series A Convertible Preferred Stock	$0.00			13,875,000	55,500	Indirect

Expiration Date	Amount	Remaning Holdings	Nature of Ownership
	2,978,500	11,914	Indirect
	13,875,000	55,500	Indirect

Footnotes

Fairmount Funds Management LLC and Fairmount Healthcare Fund GP LLC have voting power and investment power over the shares of Common Stock and Series A Preferred Stock held by Fairmount Healthcare Fund LP ("Fund I"). They disclaim beneficial ownership of securities held by Fund I for purposes of Rule 16a-1(a)(2), except to the extent of their pecuniary interest therein.
Fairmount Funds Management LLC and Fairmount Healthcare Fund II GP LLC have voting power and investment power over the shares of Common Stock and Series A Preferred Stock held by Fairmount Healthcare Fund II LP ("Fund II"). They disclaim beneficial ownership of securities held by Fund II for purposes of Rule 16a-1(a)(2), except to the extent of their pecuniary interest therein.
Each share of Series A Preferred Stock is convertible into shares of Common Stock at any time at the option of the holder thereof, into 250 shares of Common Stock, subject to certain limitations, including that a holder of Series A Preferred Stock is prohibited from converting shares of Series A Preferred Stock into shares of Common Stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than 19.99% of the total number of shares of Common Stock issued and outstanding immediately after giving effect to such conversion.